Free tool
FAERS Monitor: Oncaspar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103411 or its brand name (Oncaspar, Pegaspargase). Reports on generic versions are filed under their own applications.
Reports
12,377
Serious
12,121
98% of reports
Hospitalization
7,575
Death reported
1,593
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia1,611
- pyrexia785
- febrile bone marrow aplasia684
- vomiting611
- neutropenia597
- sepsis572
- abdominal pain516
- hypotension472
- hypertriglyceridaemia419
- pancreatitis418
- thrombocytopenia418
- nausea409
- hyperbilirubinaemia380
- pneumonia369
- off label use353
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 43 |
| 2006 | 43 |
| 2007 | 48 |
| 2008 | 23 |
| 2009 | 111 |
| 2010 | 77 |
| 2011 | 86 |
| 2012 | 120 |
| 2013 | 121 |
| 2014 | 131 |
| 2015 | 277 |
| 2016 | 499 |
| 2017 | 1,166 |
| 2018 | 2,817 |
| 2019 | 935 |
| 2020 | 810 |
| 2021 | 881 |
| 2022 | 1,708 |
| 2023 | 742 |
| 2024 | 757 |
| 2025 | 528 |
| 2026 | 415 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,782 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile bone marrow aplasiaSignal | 684 | 325.7 | 300.7 | 185,593 |
| hypertriglyceridaemiaSignal | 419 | 130.9 | 118.7 | 50,051 |
| hyperbilirubinaemiaSignal | 380 | 64.7 | 58.5 | 22,901 |
| febrile neutropeniaSignal | 1,611 | 42.3 | 40.4 | 63,502 |
| pancreatitisSignal | 418 | 13.5 | 12.3 | 4,816 |
| sepsisSignal | 572 | 8.8 | 8.1 | 3,922 |
| neutropeniaSignal | 597 | 7.5 | 6.9 | 3,358 |
| thrombocytopeniaSignal | 418 | 6.4 | 5.8 | 1,891 |
| hypotensionSignal | 472 | 4.0 | 3.7 | 1,069 |
| pyrexiaSignal | 785 | 3.9 | 3.6 | 1,686 |
| abdominal painSignal | 516 | 3.8 | 3.5 | 1,059 |
| vomitingSignal | 611 | 2.2 | 2.0 | 412 |
| pneumonia | 369 | 1.9 | 1.8 | 169 |
| nausea | 409 | 0.9 | 0.8 | 7 |
| off label use | 353 | 0.7 | 0.6 | 53 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.